Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Jiangsu Provincial Center for Disease Control and Prevention · National Institutes for Food and Drug Control · +6 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,453
total citations
- FWCI
- 224.80
- Percentile
- 100%
- References
- 36
Citations per year
Authors
21- FZFengcai ZhuCorresponding
Jiangsu Provincial Center for Disease Control and Prevention
- YLYu-Hua Li
National Institutes for Food and Drug Control
- XGXu-Hua Guan
Hubei Provincial Center for Disease Control and Prevention
- LHLi-Hua Hou
- WWWen-Juan Wang
Jiangsu Provincial Center for Disease Control and Prevention, Tongji Hospital, Huazhong University of Science and Technology
Topics & keywords
Topics
Keywords
- Medicine
- Tolerability
- Immunogenicity
- Adverse effect
- Vaccination
- Virology
- Immunology
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.